SEC-sourced researchBeta

TNXP

Tonix Pharmaceuticals Holding Corp.

US markets

Data passport

CIK: 0001430306
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Oct 2, 2026
SEC registry record: Operating company

Last updated: Oct 6, 2026, 5:01 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

TNXP · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2024	10,094,000.0000	Mar 12, 2026
December 2025	13,107,000.0000	Mar 12, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	13,107,000.0000	-124,021,000.0000	-99,844,000.0000	277,171,000.0000	32,021,000.0000	Mar 12, 2026
December 2024	10,094,000.0000	-130,036,000.0000	-60,925,000.0000	162,890,000.0000	23,332,000.0000	Mar 12, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$13.11M	December 2025	Mar 12, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$10.09M	December 2024	Mar 12, 2026	10-K
Net incomeNetIncomeLoss	-$124.02M	December 2025	Mar 12, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$99.84M	December 2025	Mar 12, 2026	10-K
Total assetsAssets	$277.17M	December 2025	Mar 12, 2026	10-K
Total liabilitiesLiabilities	$32.02M	December 2025	Mar 12, 2026	10-K

New filings

Explore methodology ↗